Psych Congress NetworkEvenamide Shows Benefit as Add-On Therapy for Treatment-Resistant Schizophrenia

Post-hoc analyses of two phase II/III trials found evenamide, a glutamate modulator, produced clinically meaningful gains when added to existing antipsychotics in treatment-resistant schizophrenia. 55% of patients no longer met TRS severity criteria after one year, and approximately one-quarter achieved full remission.

🧠 Clinical Considerations

• Evenamide showed statistically significant symptom reduction in patients with both single and multiple prior antipsychotic failures, suggesting benefit regardless of treatment history depth.
• Improvements extended to social functioning and life engagement via PANSS subdomains, outcomes that dopamine-targeting antipsychotics consistently fail to address.
• Targeting hippocampal glutamate dysregulation rather than dopamine pathways alone represents a mechanistically distinct approach to TRS management.
• Findings are post-hoc and include open-label data; phase III randomized controlled trials are underway before clinical adoption is warranted.

🎯 Practice Applications

• Identify TRS patients in your panel who have failed two or more antipsychotic trials as candidates for future evenamide eligibility.
• Monitor phase III trial results for evenamide as a potential first non-dopaminergic adjunctive option for TRS.
• Assess social functioning and life engagement at baseline using PANSS subdomains to capture full treatment response beyond symptom scores.
• Discuss glutamatergic mechanisms with patients frustrated by partial antipsychotic response as a rationale for emerging treatment approaches.

More in Schizophrenia